Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Letrozole warranted for postmenopausal breast cancer

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Letrozole warranted for postmenopausal breast cancer. Pharmacoecon. Outcomes News 438, 9 (2003). https://doi.org/10.1007/BF03277039

    Download citation

    Keywords

    • Breast Cancer
    • Tamoxifen
    • Letrozole
    • Postmenopausal Breast Cancer
    • Lifetime Cost